Cedars-Sinai Cancer study shows hormone therapy + pelvic lymph node treatment improves survival in prostate cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Research from Cedars-Sinai Cancer showed that a combination of androgen deprivation therapy plus pelvic lymph node radiation kept nearly 90% of clinical trial patients’ prostate cancer at bay for five years. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Over the past five years, Cedars-Sinai Cancer has built an integrated, regional system designed to provide cancer care close to where patients live and work. This model of care, directed by an academic medical center to patients at the community level, proved to be the best possible approach to supporting patients in our 11-million-person catchment area during the worst fire disaster in California history. 
EDAP TMS SA, the global leader in robotic energy-based therapies, announced the publication of the full results from the HIFI study in European Urology, which has the highest impact factor amongst scientific journals focused in urology. The study evaluated high-intensity focused ultrasound versus radical prostatectomy as a first line treatment of localized prostate cancer. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login